Certain 2-(1-imidazolylmethyl)pyridine compounds, having a further substituent O--Y--Z at the 3- or 5-position of the pyridine ring. Y is --(CH.sub.2).sub.n --, --CH.sub.2 C.sub.6 H.sub.4 --, or --CH.sub.2 (Het)--, where n is an integer from 1 to 4 and Het is a heterocyclic group; Z is a carboxy (COOH) or carboxycarbonyl (COCOOH) group, or an ester or amide derivative thereof. The compounds of the invention selectively inhibit the thromboxane synthetase enzyme, without significantly inhibiting the action of the prostacyclic or cyclo-oxygenase enzymes in animals, including man. The compounds are useful, therefore, in the treatment of thrombosis, ischaemic heart disease, stroke, transient ischaemic attack, migraine and the vascular complications of diabetes.

Pfizer Inc.

(Imidazolylmethyl)pyridine compounds as thromboxane synthetase inhibitors

Compounds of the general formula: ##STR1## wherein X is a group of the formula: ##STR2## m is 2 or 3; n is an integer of from 1 to 4; and R is a 5-membered heterocyclic group containing as heteroatoms a nitrogen atom and an additional oxygen or sulphur atom or up to three further nitrogen atoms; or a 6-membered heterocyclic group containing one or two nitrogen atoms;and the pharmaceutically acceptable acid addition salts thereof, are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclo-oxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine and the vascular complications of diabetes.

oxygenase/insult

(Imidazolylmethyl)pyridine compounds as thromboxane synthetase inhibitors

Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası